Anaerobutyricum soehngenii
| Anaerobutyricum soehngenii | |
|---|---|
| Scientific classification | |
| Domain: | |
| Phylum: | |
| Class: | |
| Order: | Lachnospirales
|
| Family: | |
| Genus: | |
| Species: | Anaerobutyricum soehngenii
|
| Binomial name | |
| Anaerobutyricum soehngenii Shetty et al. 2018
| |
| Type strain | |
| L2-7 (DSM 17630 = KCTC 15707) | |
Anaerobutyricum soehngenii is a species of Gram-positive, non-spore-forming, obligately anaerobic bacteria in the genus Anaerobutyricum. The species was created in 2018 when Eubacterium hallii was moved to the new genus Anaerobutyricum and strain L2-7, isolated from healthy infant feces, became the type strain.[1]
Clinical research
Early human trials indicate metabolic benefits. A two-week, first-in-human pilot in adults with metabolic syndrome showed that oral doses of viable L2-7 were safe, increased its fecal abundance and improved peripheral insulin sensitivity.[2] A crossover study found that duodenal infusion of 109 CFU L2-7 boosted post-prandial GLP-1 secretion and reduced glucose excursions.[3] More recently, a 14-day randomized, placebo-controlled trial in men with type 2 diabetes reported that daily L2-7 capsules lowered 24-hour glucose variability and systolic blood pressure without altering overall microbiota composition.[4]
References
- ^ Shetty, S. A.; Zuffa, S.; Bui, T. P. N.; Aalvink, S.; Smidt, H.; De Vos, W. M. (2018). "Reclassification of Eubacterium hallii as Anaerobutyricum hallii gen. nov., comb. nov., and description of Anaerobutyricum soehngenii sp. nov". International Journal of Systematic and Evolutionary Microbiology. 68 (12): 3741–3746. doi:10.1099/ijsem.0.003041. hdl:10138/289230. PMID 30351260.
- ^ Gilijamse, P. W.; Hartstra, A. V. (2020). "Treatment with Anaerobutyricum soehngenii: a pilot study of safety and dose–response effects on glucose metabolism in human subjects with metabolic syndrome". npj Biofilms and Microbiomes. 6: 16. doi:10.1038/s41522-020-0127-0. PMC 7101376.
- ^ Koopen, A. M.; Witjes, J. J. (2022). "Duodenal Anaerobutyricum soehngenii infusion stimulates GLP-1 production and improves glycaemic control in metabolic-syndrome subjects". Gut. 71 (8): 1577–1587. doi:10.1136/gutjnl-2020-323297. PMC 9279853.
- ^ Attaye, I.; Witjes, J. J. (2024). "Oral Anaerobutyricum soehngenii augments glycaemic control in type 2 diabetes". iScience. 27 (8): 110455. doi:10.1016/j.isci.2024.110455. PMC 11321313.